

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**022567Orig1s000**

**MEDICAL REVIEW(S)**

## CLINICAL REVIEW

Application Type NDA  
Application Number(s) 022567  
Related IND 054613  
Priority or Standard Standard

Submit Date(s) March 22, 2010  
Received Date(s) March 22, 2010  
PDUFA Goal Date January 22, 2011  
Division / Office DPP/ODE1

Reviewer Name(s) Cheri Lindberg, MD  
Review Completion Date January 19, 2011

Established Name Vilazodone HCl  
(Proposed) Trade Name Viibryd  
Therapeutic Class Antidepressant  
Applicant PGxHealth, LLC

Formulation(s) 10, 20, 40 mg tablet  
Dosing Regimen Once daily – oral  
Indication(s) Major Depressive Disorder  
Intended Population(s) Adult

Template Version: March 6, 2009

## Table of Contents

<b>1</b>	<b>RECOMMENDATIONS/RISK BENEFIT ASSESSMENT .....</b>	<b>5</b>
1.1	Recommendation on Regulatory Action .....	5
1.2	Risk Benefit Assessment.....	5
1.3	Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ...	6
<b>2</b>	<b>INTRODUCTION AND REGULATORY BACKGROUND .....</b>	<b>7</b>
2.1	Product Information .....	7
2.2	Tables of Currently Available Treatments for Proposed Indications .....	8
2.3	Availability of Proposed Active Ingredient in the United States .....	8
2.4	Important Safety Issues with Consideration to Related Drugs.....	8
2.5	Summary of Presubmission Regulatory Activity Related to Submission .....	9
2.6	Other Relevant Background Information .....	10
<b>3</b>	<b>ETHICS AND GOOD CLINICAL PRACTICES.....</b>	<b>11</b>
3.1	Submission Quality and Integrity .....	11
3.2	Compliance with Good Clinical Practices .....	11
3.3	Financial Disclosures.....	12
<b>4</b>	<b>SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES .....</b>	<b>12</b>
4.1	Chemistry Manufacturing and Controls .....	12
4.2	Clinical Microbiology.....	13
4.3	Preclinical Pharmacology/Toxicology .....	13
4.4	Clinical Pharmacology .....	13
4.4.1	Mechanism of Action.....	13
4.4.2	Pharmacodynamics.....	14
4.4.3	Pharmacokinetics.....	14
<b>5</b>	<b>SOURCES OF CLINICAL DATA.....</b>	<b>15</b>
5.1	Tables of Studies/Clinical Trials .....	15
5.2	Review Strategy .....	20
5.3	Discussion of Individual Studies/Clinical Trials.....	20
<b>6</b>	<b>REVIEW OF EFFICACY .....</b>	<b>39</b>
	Efficacy Summary.....	39
6.1	Indication – Major Depressive Disorder.....	39
6.1.1	Methods .....	39
6.1.2	Subject Disposition.....	43
6.1.2	Demographics .....	45
6.1.4	Analysis of Primary Endpoint(s).....	48
6.1.5	Analysis of Secondary Endpoints(s) .....	49
6.2.0	Efficacy Conclusions.....	64

<b>7</b>	<b>REVIEW OF SAFETY</b>	<b>64</b>
	Safety Summary	64
7.1	Methods	65
7.1.1	Studies/Clinical Trials Used to Evaluate Safety	65
7.1.2	Categorization of Adverse Events	66
7.1.3	Pooling of Data across Studies/Clinical Trials to Estimate and Compare Incidence	66
7.2	Adequacy of Safety Assessments	67
7.2.1	Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations	67
7.2.2	Explorations for Dose Response	69
7.2.3	Special Animal and/or In Vitro Testing	70
7.2.4	Routine Clinical Testing	70
7.2.5	Metabolic, Clearance, and Interaction Workup	71
7.2.6	Evaluation for Potential Adverse Events for Similar Drugs in Drug Class	71
7.3	Major Safety Results	73
7.3.1	Deaths	73
7.3.2	Nonfatal Serious Adverse Events	73
7.3.3	Dropouts and/or Discontinuations	87
7.4	Supportive Safety Results	93
7.4.1	Common Adverse Events	93
7.4.2	Laboratory Findings	97
7.4.3	Vital Signs	103
7.4.4	Electrocardiograms (ECGs)	106
7.4.5	Special Safety Studies/Clinical Trials	111
7.5	Other Safety Explorations	116
7.5.3	Drug-Demographic Interactions	118
7.5.4	Drug-Disease Interactions	119
7.5.5	Drug-Drug Interactions	119
7.6	Additional Safety Evaluations	119
7.6.1	Human Carcinogenicity	123
7.6.2	Human Reproduction and Pregnancy Data	123
7.6.3	Pediatrics and Assessment of Effects on Growth	124
7.6.4	Overdose, Drug Abuse Potential, Withdrawal and Rebound	124
<b>8</b>	<b>POSTMARKET EXPERIENCE</b>	<b>125</b>
<b>9</b>	<b>APPENDICES</b>	<b>126</b>
9.2	Labeling Recommendations	126
9.3	Advisory Committee Meeting	126

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.